Citigroup’s Coherus Oncology CHRS Stock Holding History
Bought
Maintained
Sold
Other funds holding CHRS
TGY2IT
CM
Citigroup's CHRS Position: Q3 2026 in Review
Citigroup increased its Coherus Oncology (CHRS) stake by 140% in Q3 2026, buying an estimated $123K and bringing the position to 154,112 shares worth $186K. The position accounts for ﹤0.01% of the portfolio, ranked #4231.
Citigroup first reported a position in CHRS in Q4 2014 and has held it in 48 quarters since. The position peaked at $12.7M in Q4 2021. 135 funds tracked by Wall St. Rank hold CHRS as of Q3 2026.
- Citigroup held 154,112 shares of Coherus Oncology worth $186K as of Q3 2026.
- Citigroup bought 89,770 Coherus Oncology shares in Q3 2026, an estimated $123K.
- Coherus Oncology made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #4231 holding.
- Citigroup first reported a position in Coherus Oncology in Q4 2014 and has held it in 48 quarters since.
- Citigroup's Coherus Oncology position peaked at $12.7M in Q4 2021.
- 135 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2026.
Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.